Show simple item record

dc.contributor.editorHegde, Muralidhar L.
dc.date.accessioned2021-04-20T16:20:34Z
dc.date.available2021-04-20T16:20:34Z
dc.date.issued2020
dc.identifierONIX_20210420_9781838805814_2998
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/67638
dc.description.abstractA flurry of recent research on the role of the RNA/DNA-binding proteins TDP-43 and FUS as well as a dozen other factors (e.g., C9ORF72 and profilin) has led to a new paradigm in our understanding of the pathobiology of the motor neuron disease, Amyotrophic Lateral Sclerosis (ALS). How these factors trigger neuromuscular dysfunction is critical for developing more effective ALS therapeutics. The ‘gain-of-toxicity’ or ‘loss-of-function’ of these etiological factors is a key question. Recent studies on the imbalance in genome damage versus repair have opened avenues for potential DNA repair-based therapeutics. This book highlights emerging science in the area of ALS and discusses key approaches and mechanisms essential for developing a cure for ALS.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKJ Neurology and clinical neurophysiologyen_US
dc.subject.otherNeurology & clinical neurophysiology
dc.titleAmyotrophic Lateral Sclerosis
dc.title.alternativeRecent Advances and Therapeutic Challenges
dc.typebook
oapen.identifier.doi10.5772/intechopen.78121
oapen.relation.isPublishedBy78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6
oapen.relation.isbn9781838805814
oapen.relation.isbn9781838805807
oapen.relation.isbn9781838805821
oapen.imprintIntechOpen
oapen.pages160


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/3.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/3.0/